Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DDI/DDC drugs comparative trial

Executive Summary

National Institute of Allergy and Infectious Disease will begin a comparative trial of Bristol-Myers Squib's DDI and Hoffmann-LaRoche's DDC at 18 centers as part of the Community Programs for Clinical Research on AIDS Program. The two-year study will compare disease progression, frequency and severity of side effects, and effects on CD4 counts in 400 HIV-infected patients aged 13 years or older who have previously received AZT, have a T4 cell count of 300 or less, are receiving prophylaxis against Pneumocystis carinii pneumonia, or have an AIDS-defining illness. Patients will be accrued over one year then followed in regular clinical visits for another year.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS018616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel